GLP-1s across the District's own health programs

What changed, and what the document says

1. What the Alliance will not pay for

   Not covered

   The exclusion is absolute on its face, and the clause about medical necessity is part of it rather than an exception to it.

   “No coverage, branded or generic, and even if deemed medically necessary, for: • Anti-obesity medications”

   Government of the District of Columbia, Department of Health Care Finance (DHCF) — Version 1.0 (9/9/25)

2. What it does pay for

   Conditions apply

   A named, limited generic formulary, administered by a pharmacy benefit manager rather than by the agency.

   “A limited number of generic prescription medications are covered. Please refer the Prime Limited Alliance Formulary.”

   Government of the District of Columbia, Department of Health Care Finance (DHCF) — Version 1.0 (9/9/25)

3. What it costs at the counter

   Covered

   For the medicines that are on that formulary, nothing. The barrier here is the list, not the price.

   “There are no premiums and no copayments or other charges for medical services covered by Health Care Alliance. There is a zero ($0) dollar copay for prescriptions.”

   Government of the District of Columbia, Department of Health Care Finance (DHCF) — Version 1.0 (9/9/25)

4. Generic only, from January

   Conditions apply

   A brand-name prescription stopped being reimbursable for Alliance patients on the first day of 2026.

   “Beginning on this date, coverage for prescription medications will continue to be generic-only formulations where an FDA-approved generic equivalent is available.”

   Government of the District of Columbia, Department of Health Care Finance — Office of the Senior Deputy Director and Medicaid Director — December 29, 2025

5. The three ways past it

   Context

   The transmittal names them: no generic exists, the drug is on an exception list, or a medical-necessity request is approved.

   “Brand-name medications will no longer be reimbursed unless a generic alternative is unavailable, the medication is on the exception list, or a medical necessity exception is approved.”

   Government of the District of Columbia, Department of Health Care Finance — Office of the Senior Deputy Director and Medicaid Director — December 29, 2025

6. What the letters mean on the employees' list

   Conditions apply

   Mounjaro, Ozempic and Rybelsus each appear on the 2026 District employees' list carrying both markers — a notification before coverage is decided, and a ceiling on how much is dispensed.

   “Quantity limits — The largest quantity of medication covered per copayment or in a defined period of time.”

   UnitedHealthcare, published by the DC Department of Human Resources (DCHR) — Effective January 1, 2026

7. Who writes that list

   Context

   Not the District. The employees' drug list is published by its human resources department but decided by the insurer's own committee.

   “The UnitedHealthcare® Pharmacy and Therapeutics Committee, which includes both internal and external doctors and pharmacists, meets regularly to provide clinical reviews of all medications.”

   UnitedHealthcare, published by the DC Department of Human Resources (DCHR) — Effective January 1, 2026

What the District didn't publish

The 2026 drug list published for District government employees contains no medication approved for weight management, and does not print the word weight anywhere.

We checked all 90 pages of the 2026 DC Government Employees Prescription Drug List.

In the 90-page drug list for District government employees, Ozempic appears 4 times, Mounjaro twice, Rybelsus twice, Trulicity twice and liraglutide twice. Those pages contain no occurrences of Wegovy, Zepbound, Saxenda, obesity, anti-obesity, appetite or weight. These findings describe the employee plan's drug list, not the District's Medicaid formulary.

Source: Your 2026 Prescription Drug List — DC Government Employees, UnitedHealthcare, published by the DC Department of Human Resources (DCHR).

Which of these companies serve the District of Columbia?

Of the 387 companies we grade, 34 publish a list of the states they are licensed in. We checked 251 more and found no such list on any page we read; 102 we have not checked either way.

9 of those lists name the District of Columbia: Vita Bella, TelePeptide, Wisp, Ways2Well, Trimi, Enhance MD, HumeCare+, Mojoon, and Mixx Health & Wellness. That is a licensure claim each company makes about itself, not something we checked with a state board.

A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.

Coverage decides what you pay before cash does. See how state Medicaid programs cover GLP-1s and what a prior-authorization denial turns on.